Deepika vegiraju at 08:12, 1 September 2022

2022-09-01T08:12:03Z

New page

== '''What is Tucatinib?''' ==

* Tucatinib ('''Tukysa''') is a [[kinase inhibitor]] indicated in combination with [[trastuzumab]] and [[capecitabine]] for treatment of adult patients with advanced unresectable or [[metastatic]] [[HER2 positive|HER2-positive]] [[breast cancer]].

[[File:Tucatinib.svg|thumb]]

<youtube>
title='''{{PAGENAME}}'''
movie_url=http://www.youtube.com/v/v=ce_mbnof7U8
embed_source_url=http://www.youtube.com/v/v=ce_mbnof7U8
&rel=1
wrap = yes
width=750
height=600
</youtube>

== '''What are the uses of this medicine?''' ==

This medicine is used with the medicines [[trastuzumab]] and [[capecitabine]] to treat adults with:
* human epidermal growth factor receptor-2 ([[HER2 positive|HER2) positive]] breast cancer that has spread to other parts of the body such as the brain ([[metastatic]]), or that cannot be removed by surgery, and
* who have received one or more anti-HER2 breast cancer treatments.

== '''How does this medicine work?''' ==

<youtube>
title='''{{PAGENAME}}'''
movie_url=http://www.youtube.com/v/=Gcdc2P-JVyE
embed_source_url=http://www.youtube.com/v/=Gcdc2P-JVyE
&rel=1
wrap = yes
width=750
height=600
</youtube>

* '''Tucatinib''' An orally bioavailable inhibitor of the human [[epidermal growth factor]] receptor tyrosine kinase ErbB-2 (also called HER2) with potential [[antineoplastic]] activity.
* '''Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells'''.
* ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular [[proliferation]] and [[differentiation]].

== '''Who Should Not Use this medicine ?''' ==

* This medicine have no usage limitations.

== '''What drug interactions can this medicine cause?''' ==

Avoid [[concomitant]] use with :
* strong CYP3A inducers or moderate CYP2C8 inducers.
* Strong CYP2C8 Inhibitors
* CYP3A Substrates
* P-gp Substrates

== '''Is this medicine FDA approved?''' ==

* It was approved for use in the United States in 2020.

== '''How should this medicine be used?''' ==

'''Recommended Dosage'''
* The recommended dosage of Tukysa is '''300 mg taken orally twice daily''' in combination with trastuzumab and capecitabine until disease progression or unacceptable toxicity.
* For patients with '''severe hepatic impairment, the recommended dosage is 200 mg orally twice daily'''.

'''Administration'''
* Take Tukysa exactly as your healthcare provider tells you.
* Tukysa is used with the medicines trastuzumab and capecitabine. Your healthcare provider will tell you the dose of trastuzumab and capecitabine you will take and how you will receive them.
* Take Tukysa 2 times a day, with or without a meal.
* Take Tukysa about 12 hours apart or at the same times every day.
* Swallow Tukysa tablets whole. Do not chew, crush, or split Tukysa tablets before swallowing. Do not take Tukysa tablets if they are broken, cracked, or damaged.
* If you vomit or miss a dose of Tukysa, take your next dose at your regular time.

== '''What are the dosage forms and brand names of this medicine?''' ==

This medicine is available in fallowing doasage form:
* '''As Tablets:''' 50 mg and 150 mg

This medicine is available in fallowing brand namesː
* '''Tukysa'''

=='''What side effects can this medication cause?'''==

Common possible side effects and laboratory abnormalities of this medicine include:
* [[diarrhea]]
* rash, redness, pain, swelling or blisters on the palms of your hands or soles of your feet
* [[nausea]]
* tiredness
* increased liver function blood tests
* vomiting
* mouth sores ([[stomatitis]])
* decreased appetite
* stomach-area (abdomen) pain
* headache
* low red blood cell counts ([[anemia]])
* rash

Tukysa may cause serious side effects, including:
* '''Diarrhea:''' Diarrhea is common with Tukysa and can sometimes be severe.
* '''Liver Problems:''' Tukysa can cause severe liver problems.

==''' What special precautions should I follow?''' ==

* Severe [[diarrhea]], including [[dehydration]], acute kidney injury, and death, has been reported. Administer antidiarrheal treatment as clinically indicated. Interrupt dose, then dose reduce, or permanently discontinue Tukysa based on severity.
* Severe [[hepatotoxicity]] has been reported on Tukysa. Monitor ALT, AST and bilirubin prior to starting Tukysa, every 3 weeks during treatment and as clinically indicated. Interrupt dose, then dose reduce, or permanently discontinue Tukysa based on severity.
* Tukysa can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.

== '''What to do in case of emergency/overdose?''' ==

* {{overdose}}

== '''Can this medicine be used in pregnancy?''' ==

* Tukysa can cause fetal harm when administered to a pregnant woman.
* There are no available human data on Tukysa use in pregnant women to inform a drug-associated risk.

=='''Can this medicine be used in children?'''==

* The safety and effectiveness of Tukysa in pediatric patients have not been established.

== '''What should I know about storage and disposal of this medication?''' ==

* Store at controlled room temperature, 20ºC to 25ºC (68ºF to 77ºF); excursions permitted from 15ºC to 30ºC (59ºF to 86ºF) .
* Dispense to patient in original container only. Store in original container to protect from moisture.
* Replace cap securely each time after opening. Do not discard desiccant.
* Once opened, use within 3 months.
* Discard any unused tablets 3 months after opening the bottle.

{{Extracellular chemotherapeutic agents}}
{{Growth factor receptor modulators}}
{{Portal bar | Medicine}}

[[Category:Antineoplastic drugs]]
[[Category:Breakthrough therapy]]
[[Category:Cancer treatments]]
[[Category:Orphan drugs]]
[[Category:Quinazolines]]
[[Category:Receptor tyrosine kinase inhibitors]]
[[Category:Triazolopyridines]]
{{coststubd}}

Tucatinib - Revision history

Deepika vegiraju at 08:12, 1 September 2022